FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza
October 24, 2018 — Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
“This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical. This novel drug provides an important, additional treatment option,” said FDA Commissioner Scott Gottlieb, M.D. “While there are several FDA-approved antiviral drugs to treat flu, they’re not a substitute for yearly vaccination. Flu season is already well underway, and the U.S. Centers for Disease Control and Prevention recommends getting vaccinated by the end of October, as seasonal flu vaccine is one of the most effective and safest ways to protect yourself, your family and your community from the flu and serious flu-related complications, which can result in hospitalizations. Yearly vaccination is the primary means of preventing and controlling flu outbreaks.”
Flu is a contagious respiratory illness caused by influenza viruses. When patients with the flu are treated within 48 hours of becoming sick, antiviral drugs can reduce symptoms and duration of the illness.
“When treatment is started within 48 hours of becoming sick with flu symptoms, antiviral drugs can lessen symptoms and shorten the time patients feel sick,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research. “Having more treatment options that work in different ways to attack the virus is important because flu viruses can become resistant to antiviral drugs.”
The safety and efficacy of Xofluza, an antiviral drug taken as a single oral dose, was demonstrated in two randomized controlled clinical trials of 1,832 patients where participants were assigned to receive either Xofluza, a placebo, or another antiviral flu treatment within 48 hours of experiencing flu symptoms. In both trials, patients treated with Xofluza had a shorter time to alleviation of symptoms compared with patients who took the placebo. In the second trial, there was no difference in the time to alleviation of symptoms between subjects who received Xofluza and those who received the other flu treatment.
The most common adverse reactions in patients taking Xofluza included diarrhea and bronchitis.
Xofluza was granted Priority Review under which the FDA’s goal is to take action on an application within an expedited time frame where the agency determines that the drug, if approved, would significantly improve the safety or effectiveness of treating, diagnosing or preventing a serious condition.
The FDA granted approval of Xofluza to Shionogi & Co., Ltd.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Posted: October 2018
Xofluza (baloxavir marboxil) FDA Approval History
- Recommendations Issued for HSCT in Multiple Myeloma
- Deep brain stimulation provides sustained relief for severe depression
- “Statistical significance” may soon be a thing of past?
- Researchers track effects of epigenetic marks carried by sperm chromosomes
- AHA News: Family Adopts Three Children With Three Different Heart Conditions
- Research into opioid painkillers could provide clues for safer drug development
- Lung cancer survivor recounts her lifetime struggles
- Radial and femoral approach for PCI achieve similar results in terms of survival
- Study sheds light on the optimal timing of coronary angiography in NSTEMI patients
- Excess hormones could cause a condition that can lead to blindness in women, study finds
- Dramatic shifts in first-time opioid prescriptions bring hope, concern
- Antidepressant drugs may not work when neurons are out of shape
- TTUHSC El Paso to establish endowed chair in neurology through a major grant
- New device approved by FDA for treating patients with moderate-to-severe heart failure
- People with peripheral artery disease have lower Omega-3 Index, shows research
- Trigger warnings have minimal impact on how people respond to content, shows research
- Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
- Selfish genetic elements amplify inflammation and age-related diseases
- Study provides new understanding of how the brain recovers from damage caused by stroke
- CRISPR/Cas libraries could revolutionize drug discovery